Crescendo Bioscience Announces Results from a Meta-Analysis of Studies with Vectra® DA at the 2017 Annual European Congress of Rheumatology

Data from >800 Patients Shows that a High Vectra DA Score is Associated with an Increased Risk of Joint Damage and Is More Predictive than Conventional Measures of RA SALT LAKE CITY, June 15, 2017 – Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data from a meta-analysis of […]

Read More

Crescendo Bioscience Announces Six Studies with Vectra® DA Will Be Presented at the 2017 Annual European Congress of Rheumatology

Clinical Utility of Vectra® DA Further Demonstrated with New Data on Prediction of Joint Damage SALT LAKE CITY, June 8, 2017 – Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data on the use of the Vectra® DA test will be presented at the European League Against Rheumatism (EULAR) […]

Read More

United Rheumatology Issues Clinical Practice Guidelines and Recommends the Vectra® DA Test for Adults with Rheumatoid Arthritis

SALT LAKE CITY, Utah, Dec. 22, 2016 – Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced that United Rheumatology, a leading professional organization for rheumatologists in the United States with more that 300 members, has added Vectra® DA to its clinical practice guidelines for adults with rheumatoid arthritis (RA). The […]

Read More

Crescendo Bioscience Announces Four Studies with Vectra® DA Will Be Presented at the American College of Rheumatology 2016 Annual Meeting

Studies Advance the Knowledge of Vectra DA Utility for Clinicians and Patients with RA SALT LAKE CITY, Utah,  Nov. 12, 2016 – Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced that four poster presentations on Vectra® DA will be featured at the American College of Rheumatology (ACR) meeting being held […]

Read More